{"id":832896,"date":"2025-04-02T08:39:26","date_gmt":"2025-04-02T12:39:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\/"},"modified":"2025-04-02T08:39:26","modified_gmt":"2025-04-02T12:39:26","slug":"akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\/","title":{"rendered":"Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler\u00ae-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities"},"content":{"rendered":"
\n

\n Akoya\u2019s technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challenges <\/em>
\n initiative<\/em>\n <\/p>\n

\n The unprecedented scale of the initiative requires the high plex and high throughput of Akoya\u2019s PhenoCycler-Fusion platform to process thousands of patients’ samples<\/em>\n <\/p>\n

MARLBOROUGH, Mass., April 02, 2025 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company\u00ae, and SAMBAI, a team funded through the Cancer Grand Challenges initiative, today announced that Akoya\u2019s PhenoCycler-Fusion system will be the foundational spatial proteomics technology used to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research.<\/p>\n

SAMBAI, which stands for \u201cSocietal, Ancestry, Molecular and Biological Analyses of Inequalities,\u201d explains this team\u2019s overarching objective to understand the mechanisms and contributions of genetics, biology, environmental, and social determinants to cancer risk and outcomes in diverse populations, and to provide foundational knowledge for developing novel approaches to reduce cancer inequities.<\/p>\n

Team SAMBAI will focus on assessing disparate cancer outcomes in 40,000 individuals of African descent from Africa, the UK and the US and include proteomics, transcriptomics, and other data types. Teams from Johns Hopkins University, Nottingham University, Glasgow University, and King\u2019s College London will run thousands of samples on the PhenoCycler-Fusion system using panels designed to study breast, pancreatic and prostate cancers \u2013 three cancers that have a disproportionately higher rate of aggressive tumor grade and early onset in the target population.<\/p>\n

\u201cWe are excited that the PhenoCycler-Fusion is the spatial proteomics technology of choice for analyzing thousands of patient samples as part of this important initiative,\u201d said Brian McKelligon, CEO of Akoya Biosciences. \u201cA study of this size demands the high plex and high throughput of our solutions to generate data at the scale needed. We are honored to play a role in defining the factors that influence disparate outcomes in underserved populations.\u201d<\/p>\n

Cancer Grand Challenges identifies cancer\u2019s toughest challenges and funds global research teams with the greatest potential to advance cancer research and improve outcomes for people affected by cancer. Team SAMBAI will receive up to $25 million from Cancer Grand Challenges to develop the project.<\/p>\n

\u201cAs a leader in the spatial biology field, Akoya offers the best technology to assess the effect of environmental and societal factors on biology at the molecular level and on the development of cancer at the scale required for this project,\u201d said Melissa Davis, PhD, Director of the Institute of Translational Genomic Medicine at Morehouse School of Medicine and leader of team SAMBAI. \u201cFor the first time in a large population, we plan to bring all of these factors together to understand their interconnectedness and contribution to disparities in health outcomes.\u201d<\/p>\n

\n Forward Looking Statements<\/strong>\n <\/p>\n

This press release contains forward-looking statements that are based on management\u2019s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding the potential of our products and services.<\/p>\n

In some cases, you can identify forward-looking statements by the words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201congoing\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.<\/p>\n

\n About Akoya Biosciences<\/strong>\n <\/p>\n

As The Spatial Biology Company\u00ae, Akoya Biosciences\u2019 mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode\u2122 Panels and PhenoCycler\u00ae, PhenoImager\u00ae Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit\u00a0www.akoyabio.com<\/a>.<\/p>\n

\n Investor Contact:<\/strong>\n <\/p>\n

Priyam Shah<\/p>\n

\n investors@akoyabio.com<\/a>\n <\/p>\n

\n Media Contact:<\/strong>\n <\/p>\n

Ritu Mihani<\/p>\n

\n media@akoyabio.com<\/a>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Akoya\u2019s technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challenges initiative The unprecedented scale of the initiative requires the high plex and high throughput of Akoya\u2019s PhenoCycler-Fusion platform to process thousands of patients’ samples MARLBOROUGH, Mass., April 02, 2025 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company\u00ae, and SAMBAI, a team funded through the Cancer Grand Challenges initiative, today announced that Akoya\u2019s PhenoCycler-Fusion system will be the foundational spatial proteomics technology used to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research. SAMBAI, which stands for \u201cSocietal, Ancestry, Molecular and Biological Analyses of Inequalities,\u201d explains this team\u2019s overarching objective to … <\/p>\n

Continue reading “Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler\u00ae-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-832896","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAkoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler\u00ae-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler\u00ae-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Akoya\u2019s technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challenges initiative The unprecedented scale of the initiative requires the high plex and high throughput of Akoya\u2019s PhenoCycler-Fusion platform to process thousands of patients’ samples MARLBOROUGH, Mass., April 02, 2025 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company\u00ae, and SAMBAI, a team funded through the Cancer Grand Challenges initiative, today announced that Akoya\u2019s PhenoCycler-Fusion system will be the foundational spatial proteomics technology used to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research. SAMBAI, which stands for \u201cSocietal, Ancestry, Molecular and Biological Analyses of Inequalities,\u201d explains this team\u2019s overarching objective to … Continue reading "Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler\u00ae-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-02T12:39:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTAzNyM2ODQ1OTA4IzIyMDc1MDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler\u00ae-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities\",\"datePublished\":\"2025-04-02T12:39:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\\\/\"},\"wordCount\":824,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTAzNyM2ODQ1OTA4IzIyMDc1MDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\\\/\",\"name\":\"Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler\u00ae-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTAzNyM2ODQ1OTA4IzIyMDc1MDY=\",\"datePublished\":\"2025-04-02T12:39:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTAzNyM2ODQ1OTA4IzIyMDc1MDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTAzNyM2ODQ1OTA4IzIyMDc1MDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler\u00ae-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler\u00ae-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\/","og_locale":"en_US","og_type":"article","og_title":"Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler\u00ae-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities - Market Newsdesk","og_description":"Akoya\u2019s technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challenges initiative The unprecedented scale of the initiative requires the high plex and high throughput of Akoya\u2019s PhenoCycler-Fusion platform to process thousands of patients’ samples MARLBOROUGH, Mass., April 02, 2025 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company\u00ae, and SAMBAI, a team funded through the Cancer Grand Challenges initiative, today announced that Akoya\u2019s PhenoCycler-Fusion system will be the foundational spatial proteomics technology used to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research. SAMBAI, which stands for \u201cSocietal, Ancestry, Molecular and Biological Analyses of Inequalities,\u201d explains this team\u2019s overarching objective to … Continue reading \"Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler\u00ae-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-02T12:39:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTAzNyM2ODQ1OTA4IzIyMDc1MDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler\u00ae-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities","datePublished":"2025-04-02T12:39:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\/"},"wordCount":824,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTAzNyM2ODQ1OTA4IzIyMDc1MDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\/","name":"Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler\u00ae-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTAzNyM2ODQ1OTA4IzIyMDc1MDY=","datePublished":"2025-04-02T12:39:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTAzNyM2ODQ1OTA4IzIyMDc1MDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTAzNyM2ODQ1OTA4IzIyMDc1MDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akoya-biosciences-and-team-sambai-announce-selection-of-the-phenocycler-fusion-as-the-foundational-spatial-proteomics-technology-for-large-scale-study-to-address-cancer-inequities\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler\u00ae-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=832896"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832896\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=832896"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=832896"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=832896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}